Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
da Vinci Robotic Surgery Complaints to FDA Surged This Year: Report October 7, 2013 Irvin Jackson Add Your Comments An investment analysis firm is again raising concerns about Intuitive Surgical, suggesting that a troublesome number of adverse event reports have been submitted this year involving complaints of problems following da Vinci Robotic surgery. On October 3, Citron Research issued a report (PDF) warning investors that the stock price for Intuitive Surgical, the makers of the controversial da Vinci Surgical System, will continue to plummet as the FDA continues to receive large numbers of adverse event reports involving the company’s main product. Over the first eight months of 2013, more than 2,332 da Vinci robotic surgery complaints were reported to the FDA’s MAUDE (Manufacturer and User Facility Device Experience) database. This compares with 4,603 reports received for the 12 year period between 2000 and 2012. Learn More About Da Vinci Surgical Robot Lawsuit Problems following robotic surgery may be caused by the da Vinci robot. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Da Vinci Surgical Robot Lawsuit Problems following robotic surgery may be caused by the da Vinci robot. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Reports include cases of bowel perforations, serious injuries and deaths, with many of the cases appearing to be years old and only surfacing now because of the ongoing da Vinci robot lawsuits filed against Intuitive Surgical. Citron indicates that all of the complaints appear to have addendums from Intuitive Surgical that suggest the manufacturer is attempting to dodge any and all responsibility. Citron, who released a similar report late last year, said the reports on Intuitive Surgical’s business operations are helping to “raise to the forefront of public awareness the undisclosed dangers of robotic surgery and the subsequent dilemma: what happens when medical best practices collide with unbridled thirst for profits.” The report, which opens with a link to a report of an incident involving a da Vinci robot surgery complication where a woman’s colon fell out of her vagina and down to her knees during a walk on the beach, warns investors that Intuitive Surgical’s da Vinci robot problems are far from over, and predicts that the company’s stock may eventually fall to $200 after falling from the 52-week high of over $585 per share. The report reveals a massive increase in adverse event reports involving the da Vinci robot. In August 2013 alone, there were 105 injury or death reports, more than three times the rate of any prior month. What Citron found most disturbing about those reports is that 73 of them came as a result of legal mediation efforts, raising questions about how long Intuitive Surgical knew about the incidents but did not report them to the FDA. The analysts identified at least 40 reports that were one to four years old. The report about the woman whose colon literally fell out of her body after da Vinci surgery was from January 2011, but Intuitive Surgical did not tell the FDA about it until late July 2013. “Why has the FDA not opened a formal investigation into this?” Citron’s report asks. “This is real and dangerous.” The company notes that it is not saying that there is no place for da Vinci robotic surgery in medical treatment, however it is raising questions about company’s marketing practices and handling of complaints involving the safety of the robot. 2013: A Year of da Vinci Problems and Bad Press The first report by Citron on Intuitive Surgical was issued in December 2012, warning of a “gathering storm of legal liability” and predicting that the company’s stock would drop to $250 over the next 18 months. Just months after that report was issued, the company acknowledged that it faces dozens of product liability lawsuits and its stock was already down to $350. The da Vinci Surgical System is used for number of different urologic, laparoscopic, gynecologic and non-cardiovascular thoracoscopic surgical procedures and thoracoscopically assisted cardiotomy procedures. The surgical robot has been aggressively promoted in advertisements directed to consumers, promoting the device as a superior alternative to traditional surgery because it is less-invasive and results in reduced recovery time. As Intuitive Surgical’s $1.5 million robot has been used with increasing frequency at hospitals throughout the United States in recent years, a growing number of reports have surfaced involving individuals experiencing problems following robotic surgery that are caused by burns, tears and other internal injuries. Concerns have also surfaced about whether the robot is over-used and whether it provides sufficient benefits over traditional procedures in many different applications. In May, Intuitive Surgical issued a warning to health care providers about problems with the da Vinci robot cauterizing scissors, which are known as “Hot Shears”, indicating that the components may develop micro-cracks that allow electrosurgical energy to “leak” to nearby tissue and cause thermal injury or burns to internal organs. Although some critics argued that the company should have recalled the da Vinci robots, the company did not take such an action and began shipping replacement components last month that are reportedly not prone to develop these micro-cracks. In July, it was reported that a Class 2 da Vinci robot recall was issued after it was discovered that about 30 of the surgical systems were not properly tested before being distributed. Although all of the robots were subsequently tested in the field and no problems were discovered, concerns emerged about how the factory testing was not in compliance with UL standards. During a conference call July 17, Intuitive Surgical’s CEO Gary Guthart furthered the da Vinci robot controversy when he told investors that the FDA has issued a warning letter to the company about problems with the manufacturing of the company’s main product. That letter suggests that Intuitive Surgical may have known that the da Vinci had problems with electricity arcing from the surgical instruments as early as October 2011. Intuitive Surgical has scaled back sales predictions for the da Vinci, but blamed the slow down on the health care industry, instead of concerns over problems with the robot itself. As additional patients discover that complications following robotic surgery may be related to problems with the machine or training provided for surgeons, the number of da Vinci surgery lawsuits filed against Intuitive Surgical is expected to continue to increase. Tags: Da Vinci Robot, Intuitive Surgical, Investment Advisor, Investor, Investor Lawsuit, Medical Device, Robot Surgery, Surgical Error, Surgical Robot More da Vinci Robotic Surgery Lawsuit Stories Study Finds Few Benefits To Robotic Surgery Compared to Traditional Surgical Methods August 17, 2021 Robotic Surgery Linked To High Rates of Complications In Certain Procedures: Study July 21, 2015 Robotic Surgery Device to be Developed by Ethicon and Google March 31, 2015 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermCommentsThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES NEC Infant Formula Lawyers To Meet With MDL Judge Following Dismissal of First Bellwether Trial (Posted: today) Attorneys representing plaintiffs and defendants in infant formula NEC lawsuits will meet with a federal judge next month, as the litigation moves toward the next bellwether trial in August 2025. MORE ABOUT: ENFAMIL AND SIMILAC BABY FORMULA LAWSUITFDA To Investigate Whether Infant Formula Products Provide Enough Nutrition (05/16/2025)Expert Witnesses Linking Baby Formula and NEC Cleared for Trial, Despite Dismissal of First Bellwether Lawsuit (05/05/2025)Childhood Antibiotic Use Could Lead to Increased Risks of Asthma, Allergies, Other Conditions: Study (04/28/2025) Lawsuit Alleges Intracranial Meningioma From Depo-Provera Resulted in Need for Lifelong Medical Monitoring (Posted: yesterday) A Depo-Provera lawsuit claims a woman will need medical monitoring for the rest of her life, after developing an intracranial meningioma caused by the use of the birth control shot. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Lawsuit Sign Ups Expected To Continue as First Brain Tumor Cases Prepared for Trial (05/23/2025)Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (05/15/2025)Depo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025) Court Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (Posted: yesterday) Following the first federal bellwether trial expected to begin in September 2025, a group of four additional Valsartan lawsuits will be prepared for a second wave of trials. MORE ABOUT: VALSARTAN LAWSUITOrder Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)Parties Propose Schedules for Second Wave of Valsartan Bellwether Lawsuits (02/20/2025)
NEC Infant Formula Lawyers To Meet With MDL Judge Following Dismissal of First Bellwether Trial (Posted: today) Attorneys representing plaintiffs and defendants in infant formula NEC lawsuits will meet with a federal judge next month, as the litigation moves toward the next bellwether trial in August 2025. MORE ABOUT: ENFAMIL AND SIMILAC BABY FORMULA LAWSUITFDA To Investigate Whether Infant Formula Products Provide Enough Nutrition (05/16/2025)Expert Witnesses Linking Baby Formula and NEC Cleared for Trial, Despite Dismissal of First Bellwether Lawsuit (05/05/2025)Childhood Antibiotic Use Could Lead to Increased Risks of Asthma, Allergies, Other Conditions: Study (04/28/2025)
Lawsuit Alleges Intracranial Meningioma From Depo-Provera Resulted in Need for Lifelong Medical Monitoring (Posted: yesterday) A Depo-Provera lawsuit claims a woman will need medical monitoring for the rest of her life, after developing an intracranial meningioma caused by the use of the birth control shot. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Lawsuit Sign Ups Expected To Continue as First Brain Tumor Cases Prepared for Trial (05/23/2025)Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (05/15/2025)Depo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)
Court Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (Posted: yesterday) Following the first federal bellwether trial expected to begin in September 2025, a group of four additional Valsartan lawsuits will be prepared for a second wave of trials. MORE ABOUT: VALSARTAN LAWSUITOrder Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)Parties Propose Schedules for Second Wave of Valsartan Bellwether Lawsuits (02/20/2025)